Wellgistics Health Signs $105M LOI to Acquire Neuritek Therapeutics

Key Facts

1Wellgistics Health (NASDAQ: WGRX) signed a non-binding Letter of Intent to acquire Neuritek Therapeutics, a neuroscience-focused research organization.

2The proposed acquisition is valued at $105 million and is intended to be an all-stock transaction.

3The acquisition aims to expand Wellgistics' healthcare platform into innovative therapies for neurological and psychiatric disorders.

Wellgistics Health (NASDAQ: WGRX) has announced the signing of a non-binding Letter of Intent (LOI) to acquire Neuritek Therapeutics, a specialized neuroscience research organization. The proposed transaction is valued at approximately $105 million and is structured as an all-stock deal. This strategic move aims to integrate Neuritek’s innovative therapies for neurological and psychiatric disorders into Wellgistics' existing healthcare platform. By diversifying its portfolio, Wellgistics intends to complement its core pharmacy distribution services with high-growth biotech research capabilities. While the agreement marks a significant expansion milestone, the deal remains subject to final negotiations and due diligence. Investors are closely watching the development as it could significantly scale the company's revenue-generating potential in the biotech sector.